Trial Profile
A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 30 Nov 2023
Price :
$35
*
At a glance
- Drugs Dupilumab (Primary) ; Corticosteroid; Levosalbutamol; Salbutamol
- Indications Asthma
- Focus Registrational; Therapeutic Use
- Acronyms Liberty Asthma Quest; QUEST
- Sponsors Sanofi
- 25 Nov 2023 Results of post-hoc analysis from NCT02134028 and NCT02414854; investigating long-term dupilumab efficacy in reducing exacerbations across yearly seasons in patients with type 2 inflammatory asthma with and without clinical evidence of allergic asthma, published in the Annals of Allergy, Asthma and Immunology
- 01 Oct 2023 Results of post-hoc analysis of 2 studies (LIBERTY ASTHMA QUEST trial (NCT02414854) and TRAVERSE open-label extension (NCT02134028) ) assessing dupilumab efficacy, published in the Clinical and Experimental Allergy.
- 31 Aug 2023 Results post hoc analysis assessing whether the 5-item Asthma Control Questionnaire (ACQ-5) score as a useful threshold to identify patients with moderate-to-severe type 2 asthma and high sleep disturbance, published in the Respiratory Medicine